CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
The CD19 inhibitors market is projected to expand substantially in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NHL, ALL, NMOSD, IgG4-RD, SLE, multiple sclerosis, and other related diseases; increasing awareness of CD19-targeted therapies; and a growing pipeline of investigational drugs such as Obexelimab (Zenas BioPharma), GLPG5101 (Galapagos NV), IKS 03 (Iksuda Therapeutics), ANKTIVA + CD19 t-haNK (ImmunityBio), NKX019 (Nkarta), CABA-201 (Cabaletta Bio), CLN-978 (Cullinan Therapeutics), ATA3219 (Atara Bio), KITE-363, KITE-753, KITE-197, and KITE-363 (Gilead), PL001 (Pell Bio-Med), and others advancing through clinical trials.
LAS VEGAS, March 10, 2026 /PRNewswire/ -- DelveInsight's CD-19 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Non-Hodgkin Lymphomas (NHL), Acute Lymphoblastic Leukemia (ALL), Neuromyelitis Optica Spectrum Disorder (NMOSD), Immunoglobulin G4-related Disease (IgG4-RD), Systemic Lupus Erythematosus (SLE), Multiple Sclerosis, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging CD-19 inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
Key Takeaways from the CD-19 Inhibitors Market Report
- The total market size of CD-19 inhibitors in the leading markets is expected to surge significantly by 2034.
- In 2024, the United States holds the largest share of the CD-19 inhibitors market among the 7MM.
- The report provides the total potential number of patients in the indications, such as Non-Hodgkin Lymphomas (NHL), Acute Lymphoblastic Leukemia (ALL), Neuromyelitis Optica Spectrum Disorder (NMOSD), Immunoglobulin G4-related Disease (IgG4-RD), Systemic Lupus Erythematosus (SLE), Multiple Sclerosis, and others.
- In 2024, the total incident cases of Neuromyelitis Optica Spectrum Disorder in the 7MM were around 76K.
- Leading CD-19 inhibitors companies, such as Zenas BioPharma, Galapagos NV, Iksuda Therapeutics, ImmunityBio, Nkarta, Cabaletta Bio, Cullinan Therapeutics, Atara Bio, Gilead, Pell Bio-Med, and others, are developing novel CD-19 inhibitors that can be available in the CD-19 inhibitors market in the coming years.
- Some of the key CD-19 inhibitors in clinical trials include Obexelimab, GLPG5101, IKS 03, ANKTIVA + CD19 t-haNK, NKX019, CABA-201, CLN-978, ATA3219, KITE-363, KITE-753, KITE-197, KITE-363, PL001, and others.
Discover how big will the CD-19 inhibitors market be by 2034 @ https://www.delveinsight.com/sample-request/cd19-market-forecast?utm_source=cision&utm_medium=pressrelease&utm_campaign=scpr
Key Factors Driving the CD-19 Inhibitors Market
- Rising Prevalence of B-Cell Malignancies: A growing global burden of B-cell cancers (e.g., acute lymphoblastic leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma) is creating strong demand for targeted CD19 therapies.
- Advancements in Immunotherapy Technologies: Technological innovations, especially in CAR-T cell engineering, bispecific antibodies (e.g., CD19×CD3), and antibody-drug conjugates, are enhancing efficacy and safety, broadening therapeutic potential.
- Strong CD-19 Inhibitors Clinical Trial Landscape: The anticipated launch of emerging therapies such as Obexelimab (Zenas BioPharma), GLPG5101 (Galapagos NV), IKS 03 (Iksuda Therapeutics), ANKTIVA + CD19 t-haNK (ImmunityBio), NKX019 (Nkarta), CABA-201 (Cabaletta Bio), CLN-978 (Cullinan Therapeutics), ATA3219 (Atara Bio), KITE-363, KITE-753, KITE-197, and KITE-363 (Gilead), PL001 (Pell Bio-Med), and others are expected to propel the CD-19 inhibitors market growth in the coming years.
Ramandeep Singh, Senior Consultant, Forecasting and Analytics at DelveInsight, noted that this is an exciting new class of agents with great potential for development. The maturation of current studies over the next few years will lead to a better understanding of CD19 inhibitors and define their role in the therapy of cancers and autoimmune disorders.
CD-19 Inhibitors Market Analysis
- CD19 is a key target in B-cell cancers like NHL and ALL due to its high expression on malignant B cells. It's also being investigated in autoimmune conditions such as NMOSD, IgG4-RD, SLE, and multiple sclerosis, underscoring its broad therapeutic potential.
- This highlights how CD19 inhibitors span monoclonal antibodies, bispecific antibodies, ADCs, and CAR T-cell therapies designed to target the CD19 antigen on B cells.
- Current CD19-directed therapies include approved products such as MONJUVI, UPLIZNA, BLINCYTO, ZYNLONTA, BREYANZI, and AUCATZYL, which represent major advances for relapsed or refractory B-cell malignancies.
- While highly effective, CD19 inhibitors, especially CAR T-cell therapies, often cause broad B-cell depletion, increasing infection risk and impairing immune function.
- Developing CD19 inhibitors that modulate rather than deplete B cells could provide safer and more sustainable options, especially for chronic autoimmune diseases.
- Several key players, including Zenas BioPharma, Galapagos NV, Iksuda Therapeutics, ImmunityBio, Nkarta, Cabaletta Bio, Cullinan Therapeutics, Atara Bio, Gilead, Pell Bio-Med, and others, are involved in developing drugs for CD19 inhibitors for various indications.
Learn more about which companies dominate the CD-19 / CAR-T space @ CD-19 Inhibitors Analysis
CD-19 Inhibitors Competitive Landscape
Some of the emerging CD-19 inhibitors in development include Obexelimab (Zenas BioPharma), GLPG5101 (Galapagos NV), IKS 03 (Iksuda Therapeutics), ANKTIVA + CD19 t-haNK (ImmunityBio), NKX019 (Nkarta), CABA-201 (Cabaletta Bio), CLN-978 (Cullinan Therapeutics), ATA3219 (Atara Bio), KITE-363, KITE-753, KITE-197, and KITE-363 (Gilead), PL001 (Pell Bio-Med), and others.
Zenas BioPharma's Obexelimab (XmAb5871) is a monoclonal antibody designed to bind CD19 through its variable region while engaging the inhibitory FcγRIIb receptor via Xencor's XmAb immune-inhibitor Fc domain. It is the first therapy Xencor knows of that specifically leverages FcγRIIb-mediated suppression. By strongly blocking B-cell activation without reducing B-cell numbers, Obexelimab stands apart from other B-cell–directed treatments and shows promise for a wide range of autoimmune conditions. It is currently in Phase III trials for Warm Autoimmune Hemolytic Anemia and IgG4-Related Disease, and is also being explored for Multiple Sclerosis and Systemic Lupus Erythematosus.
Galapagos' GLPG5101 is a next-generation anti-CD19/4-1BB CAR-T therapy delivered as a single fixed IV dose. Its safety, activity, and decentralized manufacturing feasibility are being investigated in the ATALANTA-1 Phase I/II trial in patients with relapsed or refractory non-Hodgkin lymphoma.
Cabaletta Bio's Rese-cel is a fully human CD19-targeting CAR-T therapy that incorporates a 4-1BB co-stimulatory domain. Cabaletta is evaluating it in the RESET Phase 1/2 programs for systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris, with potential for broader autoimmune applications.
The anticipated launch of these emerging therapies are poised to transform the CD-19 inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the CD-19 inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about how do diagnostics and early detection affect CD-19 therapy markets, visit @ CD-19 Inhibitors Treatment
Recent Developments in the CD-19 Inhibitors Market
- In February 2026, Zenas BioPharma, Inc. reported that findings from its Phase 2 MoonStone study of obexelimab in Relapsing Multiple Sclerosis were delivered as a late-breaking oral presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2026, held February 5–7, 2026, in San Diego, California.
- In October 2025, Cullinan Therapeutics presented new preclinical findings on CLN-978's B-cell depleting effects, reinforcing its potential for treating various autoimmune disorders at ACR Convergence 2025.
- In August 2025, Galapagos' experimental CD19-targeted CAR T-cell therapy, GLPG5101, was granted RMAT status by the FDA for treating relapsed or refractory mantle cell lymphoma.
- In March 2025, Bristol Myers Squibb announced that the European Commission had granted approval to BREYANZI (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
- In March 2025, Cellares, the first Integrated Development and Manufacturing Organization (IDMO), completed its Technology Adoption Program (TAP) for using the automated Cell Shuttle™ system to manufacture resecabtagene autoleucel (rese-cel, formerly CABA-201).
What are CD-19 Inhibitors?
CD-19 inhibitors are a class of biological agents designed to block or eliminate cells that display the CD19 protein, a marker found almost exclusively on B-cells, including many malignant B-cells. By targeting this surface protein, CD-19 inhibitors are used in research and certain therapeutic strategies to help reduce abnormal or cancerous B-cell populations. They are most widely associated with advanced immunotherapies, such as monoclonal antibodies and engineered cell-based treatments, that rely on recognizing CD19 to guide an immune response. Because CD19 is present throughout most stages of B-cell development, inhibiting it can significantly influence immune activity, making these agents powerful but requiring carefully controlled clinical use.
CD-19 Inhibitors Epidemiology Segmentation
The CD-19 inhibitors market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2020–2034 across the leading markets. The CD-19 inhibitors target patient pool is segmented into:
- Total Cases of Selected Indications for CD-19 Inhibitors
- Total Eligible Patient Pool for CD-19 Inhibitors in Selected Indications
- Total Treated Cases in Selected Indications for CD-19 Inhibitors
CD-19 Inhibitors Report Metrics | Details |
Study Period | 2020–2034 |
CD-19 Inhibitors Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
Key Indications Covered in the Report | Non-Hodgkin Lymphomas (NHL), Acute Lymphoblastic Leukemia (ALL), Neuromyelitis Optica Spectrum Disorder (NMOSD), Immunoglobulin G4-related Disease (IgG4-RD), Systemic Lupus Erythematosus (SLE), Multiple Sclerosis, and others |
CD-19 Inhibitors Target Patient Pool Segmentation | Total Cases of Selected Indications for CD-19 Inhibitors, Total Eligible Patient Pool for CD-19 Inhibitors in Selected Indications, and Total Treated Cases in Selected Indications for CD-19 Inhibitors |
Key CD-19 Inhibitors Companies | Zenas BioPharma, Galapagos NV, Iksuda Therapeutics, ImmunityBio, Nkarta, Cabaletta Bio, Cullinan Therapeutics, Atara Bio, Gilead, Pell Bio-Med, Autolus Therapeutics, Incyte Corporation, MorphoSys, and others |
Key CD-19 Inhibitors | Obexelimab, GLPG5101, IKS 03, ANKTIVA + CD19 t-haNK, NKX019, CABA-201, CLN-978, ATA3219, KITE-363, KITE-753, KITE-197, KITE-363, PL001, AUCATZYL, MONJUVI, and others |
Scope of the CD-19 Inhibitors Market Report
- CD-19 Inhibitors Therapeutic Assessment: CD-19 Inhibitors' current marketed and emerging therapies
- CD-19 Inhibitors Market Dynamics: Conjoint Analysis of Emerging CD-19 Inhibitors Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, CD-19 Inhibitors Market Access and Reimbursement
Discover what are the top drugs by sales or uptake rates @ CD-19 Inhibitors Clinical Trials
Table of Contents
1 | CD-19 Inhibitors Market Key Insights |
2 | CD-19 Inhibitors Market Report Introduction |
3 | Key Highlights of The Report |
4 | Executive Summary Of CD-19 Inhibitors |
5 | Key Events |
6 | Epidemiology And Market Forecast Methodology |
7 | CD-19 Inhibitors Market Overview At A Glance |
7.1 | Market Share (%) Distribution of CD-19 Inhibitors By Therapies in 2020 |
7.2 | Market Share (%) Distribution of CD-19 Inhibitors By Therapies in 2034 |
7.3 | Market Share (%) Distribution of CD-19 Inhibitors By Indications in 2020 |
7.4 | Market Share (%) Distribution of CD-19 Inhibitors By Indications in 2034 |
8 | Background And Overview |
9 | Epidemiology And Patient Population |
9.1 | Key Findings |
9.2 | Assumptions And Rationale |
9.3 | Total Cases by Indication in the 7MM |
9.4 | Total Eligible Patient Pool by Indications in the 7MM |
9.5 | Treatable Cases by Indication in the 7MM |
9.4.1 | United States |
9.4.1.1 | Cases by Indication in the United States |
9.4.1.2 | Total Eligible Patient Pool by Indications in the United States |
9.4.1.3 | Treatable Cases by Indication in the United States |
9.4.2 | EU4 and the UK |
9.4.3 | Japan |
10 | Marketed CD-19 Inhibitors |
10.1 | Key Competitors |
10.2 | AUCATZYL (obecabtagene autoleucel): Autolus Therapeutics |
10.2.1 | Product Description |
10.2.2 | Regulatory Milestones |
10.2.3 | Other Developmental Activities |
10.2.4 | Ongoing Clinical Development |
10.2.5 | Safety and Efficacy |
10.3 | MONJUVI (tafasitamab-cxix): Incyte Corporation/ MorphoSys |
11 | Emerging CD-19 Inhibitors |
11.1 | Key Competitors |
11.2 | Obexelimab: Zenas BioPharma |
11.2.1 | Product Description |
11.2.2 | Other Development Activities |
11.2.3 | Clinical Development |
11.2.3.1 | Clinical Trials Information |
11.2.4 | Safety and Efficacy |
11.3 | GLPG5101: Galapagos NV |
11.4 | IKS 03: Iksuda Therapeutics |
List to be continued… | |
12 | CD-19 Inhibitors Market: The 7MM Analysis |
12.1 | Key Findings |
12.2 | CD-19 Inhibitors Market Outlook |
12.3 | Key CD-19 Inhibitors Market Forecast Assumptions |
12.4 | Total Market Size of CD-19 Inhibitors in the 7MM |
12.5 | Market Size of CD-19 Inhibitors By Therapies In the 7MM |
12.6 | United States CD-19 Inhibitors Market |
12.6.1 | Total Market Size of CD-19 Inhibitors in the United States |
12.6.2 | Market Size of CD-19 Inhibitors By Therapies in the United States |
12.7 | EU4 and the UK CD-19 Inhibitors Market |
12.8 | Japan CD-19 Inhibitors Market |
12.8.1 | Total Market Size of CD-19 Inhibitors in Japan |
12.8.2 | Market Size of CD-19 Inhibitors By Therapies in Japan |
13 | CD-19 Inhibitors Market Unmet Needs |
14 | CD-19 Inhibitors Market SWOT Analysis |
15 | KOL Views on CD-19 Inhibitors |
16 | CD-19 Inhibitors Market Access and Reimbursement |
16.1 | United States |
16.2 | EU4 and the UK |
16.3 | Japan |
17 | Bibliography |
18 | CD-19 Inhibitors Market Report Methodology |
Related Reports
Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key non-hodgkin's lymphoma companies, including ADC Therapeutics, Bristol-Myers Squibb, Roche, Amgen, Johnson & Johnson, Celgene Corp., Mesoblast, Genmab, Novartis, Teva Pharmaceutical Industries, Karyopharm Therapeutics, AB Science, Genentech, Eli Lilly and Company, Rafael Pharmaceuticals, IO Biotech, ImmuneOnco Biopharma, Chongqing Precision Biotech, Rhizen Pharmaceuticals, Nanjing Legend Biotech, Tokalas, Arvinas, MorphoSys AG, Shanghai Genechem, Guiguidan Biomedicine (Zhongshan), Corvus Pharmaceuticals, Evive Biotech, Kite Pharma, Pfizer, Gilead Sciences, TG Therapeutics, AstraZeneca, Bayer HealthCare Pharmaceuticals, Secura Bio, BeiGene, Xynomic Pharmaceuticals, Merck & Co. Inc., Epizyme, Nordic Nanovector, Artiva Biotherapeutics, Inc., Timmune Biotech, Forty Seven, Acerta Pharma, BioInvent International, Adagene, Juventas Cell Therapy, SystImmune, Molecular Templates, Apollomics, MEI Pharma, and others.
Neuromyelitis Optica Spectrum Disorder Market
Neuromyelitis Optica Spectrum Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NMOSD companies, including RemeGen, Alexion Pharmaceuticals, Reistone Biopharma, Nihon Pharmaceutical, Harbour BioMed, Bio-Thera Solutions, Abide Therapeutics, Bionure, TG Therapeutics, ENDECE, Boston Pharmaceuticals, NovelMed, AstraZeneca, Amgen, Roche, and others.
Systemic Lupus Erythematosus Market
Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key SLE companies including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, among others.
Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key multiple sclerosis companies, including Novartis, Sanofi, AB Science, Roche, Clene Nanomedicine, InnoCare Pharma, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:
,regionOfInterest=(955,281)&hash=27c131b7533e2d4916860cc04ae4112762ad11c6c6490fc505e779e190a65bcd)
